Neal Bhadkamkar is co-founder and Managing Partner of Monitor Ventures, the early stage venture capital affiliate of The Monitor Group. He focuses on systems, industrial and life-science companies that leverage advanced information technology. In addition to Verdezyne, Neal serves on the board of Nanostellar Inc., a Stanford University spinout developing model-based design tools for advanced nano-materials, and is board observer at Matisse Networks, a company that designs and sells distributed optical switches for metro area networks. He earlier served on the board of 3DMatrix Inc., an MIT spinout commercializing self-assembling synthetic peptide scaffolds for a variety of life science applications.

Dr. Engler is Professor of Medicine, Emeritus, UCSD, in Cardiology. He was Professor of Medicine at UCSD from 1975 to 2001. His research discoveries include the role of white blood cells in reperfusion injury and capillary no-reflow, adenosine protection of the myocardium, and cardiomyocyte apoptosis. He has authored 19 book chapters and over 80 scientific publications. He was a founder of Gensia (currently Sicor), Collateral Therapeutics (sold to Schering, AG), and the Veterans Medical Research Foundation (VMRF). He served as President and Chairman of VMRF from 1992-2002.

Mr. Murdock has over 30 years experience in executive management, fund raising, marketing and business development in the biotech therapeutics and medical device industries. His tenure as CEO includes Sangstat Medical Corporation (aquired by Genzyme), Kyphon and Cellpro, Inc. At Baxter Heathcare, Rick ran the Fenwal Automation Business Unit and later The Fenwal Europe Business Unite. Rick has additional marketing and product development experience in several start-up companies including Hemascience Laboratories, Cytogen, and Haemonetics Corporation.

E. William Radany has over 25 years experience in the biotechnology industry. Prior to joining Verdezyne, he was the President and CEO of High Throughput Genomics, Inc., a provider of novel array-based gene expression assay technology for the life science industry. Previously, Dr. Radany was President of Biacore and founder and CEO of NeoGenex. Dr. Radany has held executive positions at Xencor, Caliper Technologies and Stratagene, where he helped establish business relationships with major pharmaceutical and biotechnology companies. Dr. Radany has spoken at numerous conferences and has invented several patents over the past 25 years. Dr. Radany received his Bachelor of Science degree in Cell Biology from Colorado State University and a Ph.D. in Biochemistry/Physiology from the University of Wyoming.

Dr. Senyei is a managing director at Enterprise Partners where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. Drew has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. He currently sits on the boards of Enterprise portfolio companies including: Anaborex, Ascenta Therapeutics, Celladon, Ceula, Complete Genomics, Genoptix, Ophthonix, and TargeGen.

Mr. Waite has more than 25 years of experience in both the management and investment sides of emerging growth companies. In 1987, he left his post as General Partner at Hambrecht & Quist Venture Partners to join OVP Venture Partners. Prior to that, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division. Mr. Waite earned an AB in History from Kenyon College and an MBA from Harvard University.